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Idiopathic pulmonary fibrosis (IPF), a chronic fibrosing lung disease of a progressive nature and unknown etiology,
has the largest epidemiological impact and the worst prognosis among the idiopathic interstitial pneumonias (IIP).
Despite the progress in pathogenetic knowledge, many aspects are still dubious, in particular the biomolecular
mechanisms activated in the early stages of the disease. Early diagnosis is desirable not only to better define
aspects of the natural history of the disease, but also to customize treatment protocols. An early diagnosis of IPF
should necessarily be based on the ability to highlight a number of features drawn not only from a careful
composition of specific anamnestic data with clinical, functional and radiological parameters, but also from
biological markers that, in a proper context, can provide guidance and confirm a clinical-anamnestic suspicion. The
identification of specific biomarkers for IPF is a modern and attractive look for the potential clinical implications in
terms of diagnosis, prediction of disease progression and prognosis. Biomolecular investigations on IPF were
performed selectively on tissue samples, bronchoalveolar lavage (BAL), or blood: nowadays the “multi-omic”
approach may allow studying individual constitutional profiles resorting to a series of biomolecular disciplines, the
so-called “omics”, which focuses on responses of the entire genomic complex, in line with the current trend to
quantitatively analyze the interactions of all components of a biological system. Such refined investigations are an
essential base for research now, but they might become a routine in the near future, allowing a more precise
classification of patients suffering from a disease of unclear taxonomy.
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Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing
lung disease, of a progressive nature, unknown etiology,
limited to the lung, which, in the context of the idiopathic
interstitial pneumonias (IIP), has the largest epidemiological
impact and the worst prognosis [1]. Epidemiological data
still qualify IPF as a “rare disease”, even if international
studies seem to report an increasing incidence [2,3]. It is
uncertain, however, whether this depends on the aging of
the population, changes in smoking habits, environmental
exposure to pneumotoxic substances, greater awareness
and possibilities to make a diagnosis of the disease, or a
combination of these factors [4].
Unlike other pulmonary diseases (Chronic Obstructive
Lung Disease (COPD), neoplasms), neither risk factors
nor natural history are clear for IPF. In addition, despite* Correspondence: gaeint@libero.it
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distribution, and reproduction in any mediumthe progress in pathogenetic knowledge, many aspects
are still dubious; among these, in particular the biomo-
lecular mechanisms activated in the early stages of the
disease. The most significant consequence of such un-
certainty is a delay in clinical suspicion, so that diagnosis
is usually made when clinical objectivity and anathomo-
radiological alterations have already achieved an irre-
versible expression.
The growing incidence and an inexorable progression
of IPF to functional impairment have not only directed
research towards the understanding of the pathogenesis
and molecular bases of the disease [5,6], but also en-
couraged the academic community to propose a number
of therapeutic trials [7], particularly in the last years.
These trials, however, have not provided solid and un-
equivocal efficacy [8], with one possible exception for
pirfenidone [9], on the real usefulness of which, however,
a general agreement has not been reached yet [10]. The
variability of the clinical course in each patient and theMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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explain, at least partially, the lack of consistency of the
results of such trials and the non-uniformity of inter-
pretation of the data one can find in literature. In this
context, it is notable the unavailability of trials involving
the initial stages of the disease, i.e. when the variable
pathobiological processes in progress could be, at least
in theory, reversible.
Early diagnosis is, therefore, desirable not only to
better define some aspects of the natural history of the
disease, but also to customize treatment protocols that
at this time are inevitably limited to the above mentioned
clinical trials. This in order to optimize the clinical man-
agement of patients, who are still faced with a particularly
unfavorable prognosis in the short and medium term, as
demonstrated by several survival studies [12].
However, the early diagnosis of IPF is not easy for a
number of reasons. A first difficulty is the non-specificity
of clinical symptoms at onset (non-productive cough,
exertional dyspnea). It was observed that 1 to 3 years
may elapse between the onset of symptoms and the
specialist’s assessment, while the delay in diagnosis can
even increase up to 5 years [13]. Functional evaluations
do not add to specificity of clinical suspicion: a restrictive
ventilatory defect, and a reduction in lung volumes in
particular, as well as an alteration of the diffusing cap-
acity of the lung for carbon monoxide (DLCO), are a
common feature of various interstitial lung diseases
(ILD). In addition, lung volume can remain unaltered if
there is a concomitant emphysema [14], an association
that can be justified by smoking exposure, which repre-
sents a common risk factor for both disorders.
Regarding imaging aspects, high-resolution chest tom-
ography (HRCT) is the method of choice to highlight
a pattern of usual interstitial pneumonia (UIP), the
pathological-radiological substrate of IPF, the detection
of which may be based on the distinguishing feature of
honeycombing [1]. Unfortunately, this aspect is difficult
to grasp until some more overt alterations appear, such
as the reticular pattern at the bases and in the periphery
of the lung, the presence of micro-cysts, the scarcity of
ground glass, aspects, etc. [15].
In the light of the foregoing issues, an early diagnosis
of IPF should necessarily be based on the ability to high-
light, in the very early phases of the disease, a number of
features drawn not only from a careful composition of
specific anamnestic data with clinical, functional and
radiological parameters, but also from biological markers
(biomarkers) that, in a proper context, can provide guid-
ance and confirm a clinical-anamnestic suspicion.
In general, a biomarker indicates a measurable bio-
logical characteristic (e.g. the concentration of a protein
in a biological fluid, a specific functional parameter, a
particular morphological expression in HRCT, and soon) at a certain time in a given disease, correlated with
the presence, the progression and/or therapeutic respon-
siveness of the disease [16].
The identification of specific biomarkers for IPF is a
modern look and attractive for the potential clinical im-
plications in terms of diagnosis, prediction of disease
progression and prognosis. An ideal biomarker should
be easily accessible, measurable and suitable to be used
for longitudinal assessment [17]. The need of having
such indicators available is related to several purposes.
First, to overcome limitations arising from the current
diagnostic criteria: radiological aspects are not only late,
but also sometimes not univocal in interpretation. On
the other hand, surgical biopsy is very often not feasible
for both the poor “performance status” of patients and
their refusal to undergo a surgical procedure. In any
case, a special expertise is requested for radiological and
surgical procedure and interpretation, only possible in
reference centers. Secondly, the availability of biomarkers
repeatable over time can improve the clinical management
of the patients, making it possible, for example, to provide
prognostic information and optimize the inclusion in the
lists of lung transplantation.
The identification and mapping of the human gen-
ome have led to the introduction of increasingly sophis-
ticated analytical methods and the emergence of new
molecular disciplines (genomics, transcriptomics, pro-
teomics, metabolomics: omics). Accordingly, a re-profiling
of various respiratory diseases, including IPF, took place
within a molecular approach. In this regard a biological
marker can be defined as any expression of processes
involving cells (proteins, metabolites, etc..) or of a gene
that can transmit information on the state of health or
disease of an individual and that, depending on the
type of new information provided, can be used in a
specific clinical setting (diagnosis, susceptibility, prog-
nosis, etc.) [18].
Acquisitions of genomics may be of heterogeneous
origin. The substrate most used, at least originally, was
of course the lung tissue of IPF patients, obtained from
lung biopsy, autopsy or explant [19].
In one study Selman et al. [20], employing microarrays
techniques, showed a different gene expression profile in
IPF compared to other chronic fibrosing lung diseases,
in particular the hypersensitivity pneumonitis (HP). In a
subsequent work [21] they reported a distinct biological
and transcriptional structure in patients with “slow” and
“progressive” forms of IPF.
Boon et al. [22], using a serial analysis of gene expres-
sion (SAGE), have confirmed a different gene expression
in patients with IPF compared to healthy subjects or to
patients with other respiratory conditions, and between
“stable” and “accelerated” phenotypes in the same IPF. In
addition, these AA [22] observed that some gene products
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biological fluids (blood and/or BAL).
Konishi et al. [23], still using microarray analysis, have
emphasized a “molecular signature” distinguishable in
acute exacerbations of IPF (AEIPF), and have observed
that, in cases of AEIPF, the concomitant finding of an in-
creased level of α-defensins in the blood may envisage a
clinical role for these peptides as biomarkers to be used
for patients monitoring.
The regulation of gene expression is a particularly
complex aspect, being able to modulation through not
only a transcriptional and post-transcriptional control,
but also an epigenetic one. Epigenetic is defined as the
study of changes in transcriptional profile that do not
involve changes in the DNA sequence, often in response
to environmental stimuli, and heritable through cell
generations [24]. The potential reversibility [25] of these
events explains the growing interest in the possible
therapeutic implications. Epigenomic analysis basically
is based on evaluation of DNA methylation, histone
modifications and the expression of microRNAs (miRNAs)
[26]. Extensive evidence supports the importance of epi-
genetic mechanisms in the pathogenesis of IPF.
Sanders et al. [27] found no significant differences in
global DNA methylation between normal and IPF lung,
but for IPF they reported an altered activity of some
enzymes methylating in specific anatomical regions (in
particular, fibroblastic foci), which corresponded to an
altered pattern of messenger RNA (mRNA), demonstrat-
ing the involvement of a number of disrupted genes.
Pandit et al. [28] have summarized the available data
for miRNAs, short non-coding RNA molecules involved
in post-transcriptional gene regulation and often asso-
ciated with tissue dysfunction. In IPF a fundamental
pathogenetic moment of the fibrosing process seems to
be the epithelial-mesenchymal transition (EMT), a bio-
logical phenomenon that different miRNAs can promote
(e.g. miR-2 [29], miR-155 [30]) or inhibit (e.g. Let-7d,
miR-29) [31].
The importance of these observations is not limited to
the understanding of the pathogenetic aspects only, since
they may make possible, at least theoretically, to envisage
a therapeutic strategy polarizing towards miRNAs with an
antifibrosing action [32].
Epigenetic regulation, however, may act through mul-
tiple mechanisms and interferences. An in vitro study
described the inhibition of histone deacetylation as a
possible factor for a decrease in survival of lung fibroblasts
from patients with IPF, resistant to apoptosis, through
modifications of DNA methylation [25]. Dakhlallah
et al. [33] identified in IPF a complex interactive circuit
between an aberrant DNA methylation and the regula-
tion of expression of the cluster MiR-17 ~ 92. In addition,
a pharmacological modulation causing a re-expressionof this gene cluster seemed to reduce the genes’
fibrosing potential.
Feasibility of such sophisticated strategy is, of course,
conditional upon the availability of lung tissue obtained
by way of surgical biopsy, with the consequent limita-
tions inherent to such an approach, in particular sam-
pling variability (sampling bias) [34] and risk of AEIPF
[35]. Other aspects should not be overlooked, such as
the presence of comorbidities, in a disease that typically
affects the elderly, and the mutability of interpretation
of morphological patterns. This generates the need to
make use of so-called “surrogate tissue”, i.e. biological
material obtained through partially invasive methods
(blood, BAL) [19].
The search for markers in biological fluids substan-
tially relies on serological analyses which led to the
identification of various molecules. Following the current
guidelines relating to the main pathogenetic biological
elements involved, such molecules may be divided,
according to their origin, into two categories: the com-
pounds derived from type II pneumocytes and those
derived from macrophages [36]. More recently, sub-
stances from the extracellular matrix have also been
identified as potential biomarkers [37].
Surfactant proteins A and D (SP-A, SP-D) are lipopro-
tein complexes, synthesized by type II pneumocytes (AEC
II) and by the Clara cells, mainly active in the reduction
of the surface tension, but also functioning as a defense
in the context of natural immunity. An increase in SP-A
and SP-D [38] in serum from IPF patients, was linked to
a presumed increase in the synthesis by hyperplastic
AEC IIs or to transudation resulting from decompos-
ition of the epithelium and basement membrane, and
this increase was correlated with mortality. These studies
seem therefore to suggest that SP-A and SP-D may be
potential diagnostic and prognostic biomarkers [39].
Another molecule derived from respiratory epithelium
(AEC II and bronchiolar cells) is the Krebs von den
Lungen 6 Antigen (KL6) glycoprotein, a factor of fibro-
blast proliferation and survival [40,41], whose levels
resulted high in both serum and BAL fluid [42] from
patients with various interstitial lung diseases (ILD) of
fibrosing character, both idiopathic (such as IPF and
NSIP [43]) and associated with collagen-vascular disease
[44]. Since serum levels > 1000 U/ml seem to be correlated
with survival, measuring KL6 may have a prognostic sig-
nificance in both the IIP and lung fibroses associated
with collagen-vascular diseases [45].
The chemokine CCL18, synthesized by alveolar mac-
rophages polarized towards the M2 phenotype [46], exerts
a chemotactic action on fibroblasts, stimulating their col-
lagen production [47]: CCL18 values > 150 ng/ml resulted
predictive of mortality [48], which gives a useful prognos-
tic value to this marker.
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cluding macrophages, while being correlated with the
presence of pulmonary fibrosis in general and with
the clinical course in IPF [43,49], was increased also
in other diseases so limiting its role as a biomarker.
The glycoprotein YKL-40, present in macrophages
and epithelial cells, belongs to the family of chitinases
and it regulates the growth and survival of mesenchymal
cells [50], including fibroblasts. Elevated levels of YKL-40
were detected in both serum and BAL fluid of IPF patients
[50,51] and resulted correlated with survival, so that it
might be a useful prognostic marker.
Calgranuline B (S100A9), expressed in macrophages
and neutrophils, was detected at an abnormally high level
in IPF compared to controls and other ILDs; it has
therefore been proposed as a diagnostic biomarker [52].
The matrix metalloproteinases (MMPs) constitute a
family of zinc-dependent endoproteases, involved in the
degradation of the extracellular matrix, but also in the
processing of many bioactive molecules. Rosas et al. [37]
showed that a combined increase in serum MMP1 and
MMP7 was discriminating between IPF and other ILDs
or COPD, which suggested for these molecules a diag-
nostic role and, for MMP7 only, also a prognostic one,
so that Richards et al. [53] have developed a mortality-
predictive multidimensional index involving integration
of plasmatic MMP7, FVC and DLCO.
In addition to molecular compounds, cellular elements
have been proposed as biomarkers, in particular circulat-
ing fibrocytes, i.e. cells derived from bone marrow able
to develop a mesenchymal differentiation (fibroblasts
and myofibroblasts), and Moeller et al. [54] underlined
that an increase in fibrocytes> 5% testifies a poor prog-
nosis. A role as biomarkers has been suggested also for
additional proteins (osteopontin, periostin) involved in
the pathogenesis of IPF [17].
From the above findings in the literature one may easily
gather that, regardless of etiology, various biological fac-
tors are involved and interact in the process of chronic
remodeling and fibrosis of the lung: these factors can
therefore potentially be used as biomarkers in both ILD
[55] in general and particularly in IPF [17]. Concerning
IPF, numerous studies have been conducted using bio-
molecular analyses to clarify various aspects of clinical
significance. The objectives of such works were, how-
ever, directed to the study of pathogenetic mechanisms
[56], in order to identify new therapeutic “targets”, to
diagnostic characterization of the specific phenotypes
[22] (e.g. slow vs. fast progressors) of IPF, to the identifi-
cation of the presence, extension [57] or prognosis [53]
of the disease, or, finally, to describe a “pattern” of gene
expression [20,23,58]. Biomolecular investigations on
IPF were performed selectively on tissue samples, BAL,
or blood, in a diagnostic context which had already beendefined, and not with the aim of reaching an early
diagnosis.
Conclusions
In conclusion, IPF is a progressive and fatal fibrosing
lung disease, caused by a complex and only partially
known interaction between exposure to pneumotoxic
agents and predisposing conditions. The “multi-omic”
approach may allow studying individual constitutional
profiles resorting to a series of biomolecular disciplines,
the so-called “omics”, which provide various methods
that are, at least in principle, complementary. Such an
approach implies a shift from a “gene-centric” vision of
IPF, in which a given phenotype is believed to derive
from the response of a single gene to injury, to a global
genome (“genome-wide”) vision, which focuses on re-
sponses of the entire genomic complex [19], in line with
the current trend to quantitatively analyze the interac-
tions of all components of a biological system [59] in
order to define the phenotype of various lung conditions
(“systems biology”).
In an age of “integrated” approach to respiratory dis-
eases [60], made possible by implementation of biomolec-
ular analytical technologies, and of “holistic” management
of IPF [61], the use of biological markers may be extended
from the search for molecules in blood to the identifica-
tion of gene alterations [62] (single nuclear polymor-
phisms: SNP, gene mutations), as well as epigenetic
ones [26] and changes in particular substances [63]. IPF,
therefore, does not appear as a disease from an alteration
of a single gene, although single mutations were found,
such as those concerning the coding of the telomerase
enzyme complex [64] or SNP, in particular in the gene
encoding mucin 5B (MUC5B) [65], measurable on blood
and BAL as well. These changes, however, may be regarded
not as an expression of disease, but rather as an increased
predisposing condition, while more significant clinical
information could result from methods allowing accur-
ate analyses of genetic and epigenetic expression [34,35]
(e.g., miRNA, methylation). On the other hand proteo-
mics research, being able to recognize specific protein
clusters (MMP1 and 7, SPP1, YKL-40, etc.) [17], could
complement genetic investigation and contribute to the
building of a biological “profile” of the pathology: many
of the current obstacles may be overcome through in-
creased access to data from the Lung Tissue Research
Consortium [66], founded by the National Health Insti-
tute with the aim of collecting biological and clinical
material concerning respiratory diseases, particularly
COPD and ILD.
Such refined investigations, which seem rather futuris-
tic, are an essential base for research now, but they
might become a routine in the near future, allowing a
more precise classification of patients suffering from a
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Competing interests
The authors declare that they have no competing interests.
Author details
1RespiratoryPhysiopathology Unit, ASL SA, Cava de’ Tirreni, SA, Italy. 2Senior
Consultant in Respiratory Medicine, Editor and Managing Director of
Multidisciplinary Respiratory Medicine, Rome, Italy.
Received: 8 July 2013 Accepted: 16 July 2013
Published: 9 August 2013
References
1. Raghu G: An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary
fibrosis: evidence-based guidelines for diagnosis and management. Am J
Respir Crit Care Med 2011, 183:788–824.
2. Navaratnam V, Fleming KM, West J, Smith CJP, Jenkins RG, Fogarty A,
Hubbard RB: The rising incidence of idiopathic pulmonary fibrosis in the
UK. Thorax 2011, 66:462–467.
3. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence and
prevalence of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med
2006, 174:810–816.
4. Frankel SK, Schwarz MI: Update in idiopathic pulmonary fibrosis. Curr Opin
Pulm Med 2009, 15:463–469.
5. Vancheri C, Failla M, Crimi N, Raghu G: Idiopathic pulmonary fibrosis: a
disease with similarities and links to cancer biology. Eur Respir J 2010,
35:496–504.
6. King TE Jr, Pardo A, Selman M: Idiopathic Pulmonary Fibrosis. Lancet 2011,
378:1949–1961.
7. Richeldi L: Assessing the treatment effect from multiple trials in
idiopathic pulmonary fibrosis. Eur Respir Rev 2012, 21:147–151.
8. Cottin V: Changing the idiopathic pulmonary fibrosis treatment approach
and improving patient outcome. Eur Respir Rev 2012, 21:161–167.
9. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D,
King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, Du Bois R,
CAPACITY Study Group: Pirfenidone in patients with idiopathic
pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011,
377:1760–1769.
10. Papiris SA, Kagouridis K, Kolilekas L, Triantafillidou C, Tsangaris I, Manali ED:
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a
great expectation? Eur Respir J 2012, 40:794–795.
11. Albera C: Challenges in idiopathic pulmonary fibrosis trials: the point on
end-points. Eur Respir Rev 2011, 20:195–200.
12. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr,
Flaherty KL, Schwartz DA, Noble PW, Raghu G, Brown KK, For the IPF Study
Group: The clinical course of patients with Idiopathic Pulmonary
Fibrosis. Ann Intern Med 2005, 142:963–967.
13. Kim DS, Collard HR, King TE Jr: Classification and natural history of the
idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006, 3:285–292.
14. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I,
Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF, The Grouped’Etude et de
Recherchesur les Maladies “Orpheline” Pulmonaires (GERM”O”P): Combined
pulmonary fibrosis and emphysema: a distinct underrecognised entity.
Eur Respir J 2005, 26:586–593.
15. Nashimura K, Kitaichi M, Izumi T, Nagai S, Kanaoka M, Itoh H: Usual
interstitial pneumonia: histologic correlation with high-resolution CT.
Radiology 1992, 182:337–342.
16. Thomeer M, Grutters JC, Wuyts WA, Willems S, Demedts MG: Clinical use of
biomarkers of survival in pulmonary fibrosis. Respir Res 2010, 11:89.
17. Vij R, Noth I: Peripheral blood biomarkers in idiopathic pulmonary
fibrosis. Transl Res 2012, 159:218–227.
18. Zhang Y, Kaminski N: Biomarkers in idiopathic pulmonary fibrosis. Curr Opin
Pulm Med 2012, 18:441–446.
19. Kaas DJ, Kaminski N: Evolving genomic approaches to idiopathic
pulmonary fibrosis: moving beyond genes. Clin Transl Sci 2011, 4:372–379.
20. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, Aziz N,
Kaminski N, Zlotnik A: Gene expression profiles distinguish idiopathic
pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit
Care Med 2006, 173:188–198.21. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M,
Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE Jr, Pardo A,
Kaminski N: Accelerated variant of idiopathic pulmonary fibrosis: clinical
behavior and gene expression pattern. PLoS One 2007, 5:482.
22. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK,
Schwarz MI, Schwartz DA: Molecular phenotypes distinguish patients with
relatively stable from progressive Idiopathic Pulmonary Fibrosis (IPF).
PLoS One 2009, 4:5134.
23. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglie M,
Gilbert S, Yousem SA, Song JW, Kim DS, Kaminski N: Gene expression
profiles of acute exacerbation of Idiopathic Pulmonary Fibrosis. Am J
Respir Crit Care Med 2009, 180:167–175.
24. Ecclestone A, De Witt N, Gunter C, Marte B, Nath D: Epigenetics. Nature 2007,
447:395.
25. Sanders YY, Hagood JS: The effects of histon deacetylase inhibitors on
fibrotic lung fibroblasts survival and apoptosis. Am J Respir Crit Care Med
2010, 181:A2015.
26. Yang IV, Schwartz DA: Epigenetic control of gene expression in the lung.
Am J Respir Crit Care Med 2011, 183:1295–1301.
27. Sanders YY, Ambalavanan N, Halloran B, Zhang X, Liu H, Crossman DK, Bray M,
Zhang K, Thannickal VJ, Hagood JS: Altered DNA methylation profile in
Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2012, 186:525–535.
28. Pandit KV, Milosevic J, Kaminski N: MicroRNAs in idiopathic pulmonary
fibrosis. Transl Res 2011, 157:191–199.
29. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N,
Abraham E: miR-21mediates fibrogenic activation of pulmonary
fibroblasts and lung fibrosis. J Exp Med 2010, 207:1589–1597.
30. Pottier N, Maurin T, Chevalier B, Puisségur MP, Lebrigand K, Robbe-Sermesant K,
Bertero T, Cardenas CLL, Courcot E, Rios G, Fourre S, Lo Guidice JM, Marcet B,
Cardinaud B, Barbry P, Mari B: Identification of keratinocyte growth
factor as a target of microRNA-155 in lung fibroblasts: implication in
epithelial-mesenchymal interactions. PLoS One 2009, 4:e6718.
31. Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF,
Konishi K, Yousem SA, Singh M, Handley D, Richards T, Selman M, Watkins SC,
Pardo A, Ben-Yehudah A, Bouros D, Eickelberg O, Ray P, Benos PV, Kaminski N:
Inhibition and role of let-7d in Idiopathic Pulmonary Fibrosis. Am J Respir
Crit Care Med 2010, 182:220–229.
32. Yang IV: Epigenomics of idiopathic pulmonary fibrosis. Epigenomics 2012,
4:195–203.
33. Dakhlallah D, Batte K, Wang Y, Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A,
Hitchcock CL, Wright VP, Nana-Sinkam SP, Piper MG, Marsh CB: Epigenetic
regulation of miR-17 92 contributes to the pathogenesis of Pulmonary
Fibrosis. Am J Respir Crit Care Med 2013, 187:397–405.
34. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazeroony EA, Gross BH, Jain A,
Strawdermann RL III, Flint A, Lynch JP III, Martinez FJ: Histopathologic
variability in usual and nonspecific Interstitial Pneumonias. Am J Respir
Crit Care Med 2001, 164:1722–1727.
35. Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS,
Schroeder DR: High short-term mortality following lung biopsy for usual
interstitial pneumonia. Eur Respir J 2001, 17:175–179.
36. Prasse A, Muller-Quernheim J: Non-invasive biomarkers in pulmonary
fibrosis. Respirology 2009, 14:788–795.
37. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO,
Cisneros J, MacDonald SD, Pardo A, Sciurba F, Dauber J, Seman M,
Gochuico BR, Kaminski N: MMP1 and MMP7 as potential peripheral blood
biomarkers in Idiopathic Pulmonary Fibrosis. PLoS Med 2008, 5:93.
38. Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW,
Newman LS, Nagae H, Mason RJ: Serum surfactants proteins-A and -D
as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002,
19:439–446.
39. Kinder BW, Brown KK, Mc Cormack FX, Ix JH, Kervitski A, Schwarz MI,
King TE Jr: Serum surfactant protein-A is a strong predictor of early
mortality in Idiopathic Pulmonary Fibrosis. Chest 2009, 135:1557–1563.
40. Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N: KL-6,
a human MUC1 mucin, promotes proliferation and survival of lung
fibroblasts. Biochem Biophys Res Commun 2005, 338:1845–1852.
41. Hirasawa Y, Kohno N, Yokohama A, Inoue Y, Abe M, Hiwada K: KL6, a human
MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol
1997, 17:501–507.
42. Kobayas J, Kitamura S: KL-6: A serum marker for Interstitial Pneumonia.
Chest 1995, 108:311–315.
Cicchitto and Sanguinetti Multidisciplinary Respiratory Medicine 2013, 8:53 Page 6 of 6
http://www.mrmjournal.com/content/8/1/5343. Ohnishi H, Yokoama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K,
Kohno N: Comparative study of KL-6, surfactant protein-A, surfactant
protein-D, and monocyte chemoattractant protein-1 as serum markers
for Interstitial Lung Diseases. Am J Respir Crit Care Med 2002, 165:378–381.
44. Kinoshita K, Hamano H, Harado H, Kinoshita T, Igishi T, Hagino H, Ogawa T:
Role of KL-6 in evaluating the disease severity of rheumatoid lung
disease: comparison with HRCT. Respir Med 2004, 98:1131–1137.
45. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M: Increased levels of KL-6 and
subsequent mortality in patients with interstitial lung diseases. J Intern
Med 2006, 260:429–434.
46. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The
chemokine system in diverse forms of macrophage activation and
polarization. Trends Immunol 2004, 25:677–686.
47. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldman T,
Vollmer E, Muller-Quernheim J, Zissel G: A vicious circle of alveolar
macrophages and fibroblasts perpetuates Pulmonary Fibrosis via CCL8.
Am J Respir Crit Care Med 2006, 173:781–792.
48. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschevski M,
Rottoli P, Müller-Quernheim J: Serum CC-chemokine ligand 18
concentration predicts outcome in Idiopathic Pulmonary Fibrosis. Am J
Respir Crit Care Med 2009, 179:717–723.
49. Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M: Clinical
significance of MCP- 1 levels in BALF and serum in patients with
interstitial lung diseases. Eur Respir J 1999, 14:376–382.
50. Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S, Hayakawa H,
Kusagaya H, Nakano Y, Nakamura H, Chida K: Increased expression of
YKL-40, a chitinase-like protein, in serum and lung of patients with
idiopathic pulmonary fibrosis. Respir Med 2010, 104:1204–1210.
51. Korthagen NM, Van Moorsel CHM, Barlo NP, Ruven HJT, Kruit A, Heron M,
van den Bosch JMM, Grutters JC: Serum and BALF YKL-40 levels are
predictors of survival in idiopathic pulmonary fibrosis. Respir Med 2011,
105:106–113.
52. Hara A, Sakamoto N, Ishimatsu Y, Kakugawa T, Nakashima S, Hara S, Adachi M,
Fujita H, Mukae H, Kohno S: S100A9 in BALF is a candidate biomarker of
pulmonary fibrosis. Respir Med 2012, 106:571–580.
53. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K,
Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF: Peripheral Blood
Proteins Predict Mortality in Idiopathic Pulmonary Fibrosis. Am J Respir
Crit Care Med 2012, 185:67–76.
54. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L,
Dobranowski J, Boylan C, O’Byrne PM, Strieter RM, Kolb M: Circulating
Fibrocyte Are an Indicator of Poor Prognosis in Idiopathic Pulmonary
Fibrosis. Am J Respir Crit Care Med 2009, 179:588–594.
55. Nukiwa T: Interstitial Lung Disease. In The role of biomarkers in
management of interstitial lung disease: implications of biomarkers derived
from type II pneumocytes. 46th edition. Edited by Du Bois RM, Richeldi L. ERS
Monograph; 2009:47–66.
56. Rottoli P, Bargagli E, Landi C, Magi B: Proteomic analysis in interstitial lung
diseases: a review. Curr Opin Pulm Med 2009, 15:470–478.
57. Yang IV, Luna LG, Cotter J, Talbert J, Leach SM, Kidd R, Turner J, Kummer N,
Kervitsky D, Brown KK, Boon K, Schwarz MI, Schwartz DA, Steele MP: The
Peripheral Blood Transcriptome Identifies the Presence and Extent of
Disease in Idiopathic Pulmonary Fibrosis. PLoS One 2012, 7:37708.
58. Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E, Cianti R,
Bini L, Pallini V: Cytokine profile and proteome analysis in
bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis
associated with systemic sclerosis and idiopathic pulmonary fibrosis.
Proteomics 2005, 5:1423–1430.
59. Studer SM, Kaminski N: Towards systems biology of human Pulmonary
Fibrosis. Proc Am Thorac Soc 2007, 4:85–91.
60. Center DM, Schwartz DA, Solway J, Gail D, Laposki AD, Lin QS, Gan W:
Genomic medicine and lung diseases. Am J Respir Crit Care Med 2012,
186:280–285.
61. Lee JS, McLaughlin S, Collard HR: Comprehensive care of the patient with
idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2011, 17:348–354.
62. Yang IV, Burch LH, Steele MP, Savov JD, Hollingsworth JW, McElvania-Tekippe E,
Berman KG, Speer MC, Sporn TA, Brown KK, Schwarz MI, Schwartz DA:
Gene expression profiling of familial and sporadic Interstitial
Pneumonia. Am J Respir Crit Care Med 2007, 175:45–54.
63. Danil ZD, Papageorgiou E, Koutsokera A, Kostikas K, Kiropoulos T,
Papaioannou AI, Gourgoulianis KI: Serum levels of oxidative stress as amarker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol
Ther 2008, 21:26–31.
64. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, Garcia CK:
Telomere shortening in familial and sporadic Pulmonary Fibrosis. Am J
Respir Crit Care Med 2008, 178:729–737.
65. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE,
Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB,
Dickey BF, Du Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C,
Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CM,
Schwarz MI, Schwartz DA: A common MUC5B promoter polymorphism
and Pulmonary Fibrosis. N Eng J Med 2011, 364:1503–1512.
66. Lung Genomics Research Consortium: www.lung-genomics.org.
doi:10.1186/2049-6958-8-53
Cite this article as: Cicchitto and Sanguinetti: Idiopathic pulmonary
fibrosis: the need for early diagnosis. Multidisciplinary Respiratory Medicine
2013 8:53.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
